Puma Biotechnology (PBYI) Q4 2024 earnings summary

Executive summary

• Q4 2024 total revenue was $59.1 million, with net product revenue from NERLYNX at $54.4 million and royalty revenue at $4.7 million.

• Net income for Q4 2024 was $19.3 million GAAP ($0.39/share) and $21.1 million non-GAAP ($0.43/share), both up from Q4 2023.

• NERLYNX ex-factory bottle sales in Q4 2024 were 2,964, up 9% quarter-over-quarter and 3% year-over-year.

• 74% of patients in Q4 2024 started NERLYNX at a reduced dose, supporting improved compliance.

• International expansion continued with regulatory approvals and launches in Turkey, Thailand, Saudi Arabia, South Africa, United Arab Emirates, and Algeria during 2024.

Financial highlights

• Q4 2024 net product revenue was $54.4 million, a 2% increase year-over-year but a 3% decrease from Q3 2024.

• Royalty revenue dropped significantly from $24.4 million in Q3 2024 due to lower China shipments.

• Cost of sales for Q4 2024 was $13.9 million, including $2.4 million in amortization of intangible assets.

• Cash and equivalents at year-end 2024 were $101 million, up from $96 million at year-end 2023.

• Operating costs and expenses for Q4 2024 were $45.7 million, down from $57.4 million in Q4 2023.

Outlook and guidance

• FY 2025 net NERLYNX product revenue expected between $192–$198 million.

• FY 2025 royalty revenue guidance is $20–$24 million, lower due to fewer China shipments.

• FY 2025 net income projected at $23–$28 million; Q1 2025 net product revenue expected at $41–$43 million.

• Q1 2025 anticipated net loss between $2 million and break-even due to inventory burn-off.

• Key clinical milestones expected in 2025 include interim data from multiple ongoing trials.